Kai Kang

7PUBLICATIONS
41CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunologyCardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)Context learning
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 08, 2026
SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8+ T cell immunity against bulky tumors via an IFN-I/NK/DC axis.

|Mar 07, 2025
Heterogeneity of tumor-infiltrating T cells and its impact on anti-PD-1/PD-L1 immunotherapy: insights from integrated multicancer single-cell and bulk transcriptomic analysis.

Kai Kang, Chang Han, Li Wang

|Jun 24, 2024
Letter to the Editor: Regarding the use of decision curve analysis in predicting long-term complications of liver cirrhosis.

Kai Kang, Yijun Wu

|Jun 10, 2024
CDK4/6 inhibitor abemaciclib combined with low-dose radiotherapy enhances the anti-tumor immune response to PD-1 blockade by inflaming the tumor microenvironment in Rb-deficient small cell lung cancer.

Laduona Wang, Yijun Wu, Kai Kang

|Apr 10, 2024
Embracing ChatGPT for Medical Education: Exploring Its Impact on Doctors and Medical Students.

Yijun Wu, Yue Zheng, Baijie Feng

|Aug 15, 2023
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer Patients.

Xiaojuan Zhou, Laiyan Zhou, Zhuoran Yao

Pageof 2

Frequent Collaborators

5 joint publications

Yijun Wu

3 joint publications

You Lu

2 joint publications

Zhuoran Yao

2 joint publications

Gabriele Niedermann